LINC02055: A Long Intergenic Non-Protein Coding RNA (G107986980)

Target Name: LINC02055

NCBI ID: G107986980

LINC02055

Other Name(s): long intergenic non-protein coding RNA 2055 | Long intergenic non-protein coding RNA 2055

LINC02055: A Long Intergenic Non-Protein Coding RNA

Introduction

LINC02055 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique 3'-end covered with protein binding sites, which is rare in lncRNAs. This feature makes LINC02055 an attractive candidate for potential drug targets or biomarkers. In this article, we will explore the properties of LINC02055, its potential drug-target potential, and its potential as a biomarker for various diseases.

Properties of LINC02055

LINC02055 is a 24.1-kb RNA molecule and one of the largest lncRNAs discovered so far. It consists of 1,182 nucleotides and its 5' end contains a specific protein-binding site consisting of a ribosome-binding alpha helix with two phosphorylation sites. The 6' end contains a stop codon, but there is no RNA binding site at the 5' end. LINC02055 is mainly expressed in nucleoli in cells and is conserved in RNA-binding proteins (RBPs) and nucleolar proteins (NPs).

Protein binding site of LINC02055

LINC02055's protein binding site is one of its most distinctive features. It is made up of two interacting alpha helices, one of which forms a core and the other winding around the inside. This alpha-helical structure enables LINC02055 to bind to a variety of RNA-binding proteins (RBPs), including SPOP, TBP, ZBP, and CBF1. These binding proteins can bind to the 伪-helical region of LINC02055, which may affect its stability, expression level or function.

Phosphorylation site of LINC02055

LINC02055 contains a stop codon at the 6' end but no RNA binding site at the 5' end. Stop codons are not usually found in the binding sites of RNA-binding proteins, so it can be speculated that there may be an RNA-binding site at the 5' end of LINC02055. In fact, there is indeed an RNA binding site at the 5' end of LINC02055, but it is not a conventional RNA binding site, but a special domain.

Drug-target potential of LINC02055

LINC02055's protein binding site and RNA binding site make it an attractive drug target. By interfering with the binding of RNA-binding proteins to LINC02055, it is possible to block its function and affect cell biological processes. In addition, LINC02055's expression patterns in multiple diseases also support its potential as a drug target.

Biomarker potential of LINC02055

The protein binding site and RNA binding site of LINC02055 make it a potential biomarker. By measuring the binding level of an RNA-binding protein to LINC02055, its affinity for the target protein can be assessed. In addition, by comparing the differences between LINC02055 expression levels and controls, its potential role in disease diagnosis and prognosis can be evaluated.

in conclusion

LINC02055 is a long non-coding RNA molecule with a unique protein binding site and has good drug target potential and biomarker potential. The special design of the RNA binding site at the 5' end and the stop codon at the 6' end exclude conventional RNA binding sites, allowing it to bind to a variety of RNA binding proteins. In addition, LINC02055's expression patterns in multiple diseases also support its potential as a drug target. In the future, LINC02055 will be a promising drug target or a research object as a biomarker for disease diagnosis and prognosis.

Protein Name: Long Intergenic Non-protein Coding RNA 2055

The "LINC02055 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02055 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets